Avalo Therapeutics, Inc.
Avalo Therapeutics develops monoclonal antibodies targeting the IL-1β pathway for immune-mediated inflammatory diseases.
10-KSep 22Latest SEC filing, period to Jun 30
Sep 3Latest story
August 2026
Sign inSign inAvalo Therapeutics develops monoclonal antibodies targeting the IL-1β pathway for immune-mediated inflammatory diseases.